This trade closes out the MRNA position opened on April 8, 2026. With expiration arriving today and the stock trading favorably above the $46 strike, this was a clean, disciplined exit — locking in the majority of premium before the final bell.
Trade Update
MRNA – Closing Position
- 04/17/26 – Buy to Close MRNA $46 Put (04/17) @ $33
- Closed the position on expiration day to eliminate assignment risk and secure profit.
Why I Closed It
With MRNA expiring today and the premium decayed down to $33, this was a straightforward expiration day management decision. Rather than letting it expire and risk any last-minute volatility — which MRNA is more than capable of — buying it back for $33 was the clean, low-risk move.
The original premium collected was $110. Buying it back at $33 locks in a net gain of $77 per share — roughly 70% of max profit — right in line with the 70% max-profit exit strategy.
Key Takeaways
- Expiration day discipline — MRNA is a high-IV biotech that can move fast around any catalyst; closing on expiration day removes unnecessary risk
- 70% max-profit rule delivered again — $77 captured on a $110 credit is a textbook, repeatable result
- Two clean MRNA trades in a row — closing the previous position at 69% and this one at 70% shows the strategy is working consistently on this ticker
- Capital is now fully free — with MRNA, FCX, and INTC all closed, the slate is clean and ready for the next round of opportunities
Another clean exit in the books. Capital is freed up and ready to be redeployed into the next cash-secured put. Consistency over perfection — that’s the game.